Biogen Aktie
WKN: 789617 / ISIN: US09062X1037
10.06.2024 02:48:43
|
Eisai : FDA Accepts SBLA On LEQEMBI For Early Alzheimer's Treatment
(RTTNews) - Eisai Co., Ltd. (ESALY.PK, ESALF.PK) and Biogen Inc. (BIIB) said that the U.S. Food and Drug Administration has accepted Eisai's Supplemental Biologics License Application or sBLA for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing.
A Prescription Drug User Fee Act (PDUFA) action date is set for January 25, 2025.
LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment or mild dementia stage of disease (collectively referred to as early AD).
Additionally, Eisai initiated the rolling submission of a BLA to the FDA for the LEQEMBI subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA in May 2024.
LEQEMBI is now approved in the U.S., Japan, China and South Korea, and applications have been submitted for review in the European Union, Australia, Brazil, Canada, Hong Kong, Great Britain, India, Israel, Russia, Saudi Arabia, Taiwan, Singapore, and Switzerland.
Eisai serves as the lead for lecanemab's development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.
For More Such Health News, visit rttnews.com.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Biogen Incmehr Nachrichten
22.04.25 |
Dienstagshandel in New York: NASDAQ 100 zum Ende des Dienstagshandels mit Kursplus (finanzen.at) | |
22.04.25 |
Optimismus in New York: NASDAQ 100 am Nachmittag stärker (finanzen.at) | |
22.04.25 |
Börse New York in Grün: NASDAQ 100 steigt mittags (finanzen.at) | |
22.04.25 |
Gute Stimmung in New York: NASDAQ 100 zum Handelsstart im Aufwind (finanzen.at) | |
21.04.25 |
NASDAQ Composite Index-Wert Biogen-Aktie: So viel hätten Anleger an einem Biogen-Investment von vor 10 Jahren verloren (finanzen.at) | |
17.04.25 |
Kaum Veränderungen: NASDAQ 100 letztendlich orientierungslos (finanzen.at) | |
17.04.25 |
Zuversicht in New York: NASDAQ 100 verbucht nachmittags Gewinne (finanzen.at) | |
17.04.25 |
Börse New York in Grün: NASDAQ 100 verbucht am Mittag Gewinne (finanzen.at) |
Analysen zu Biogen Incmehr Analysen
Aktien in diesem Artikel
Biogen Inc | 104,50 | -0,33% |
|